Many cancer medications fail to effectively target the most commonly mutated cancer genes in humans, called RAS. Now, Salk Professor Geoffrey Wahl and a team of scientists have uncovered details into how normal RAS interacts with mutated RAS and other proteins in living cells for the first time. The findings, published in The Proceedings of the National Academy of Sciences on May 18, 2020, could aid in the development of better RAS-targeted cancer therapeutics.
- Scientists explore the action mechanism of a new antibiotic
- Study aims to help governments maximize profits from oil and gas auctions
- Field study shows icing can cost wind turbines up to 80% of power production
- Moms need guidance on what to eat when their breastfeeding infant has a food allergy
- A parental paradox for Black girls in the justice system